MedTrace Logo

The Potential of Carnosine Supplementation in Reducing the Cardiometabolic Risk

NCT02686996 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2018-03-22

No results posted yet for this study

Summary

The aim of this study is to determine whether carnosine supplementation in overweight/obese individuals can improve insulin secretion and/or insulin resistance by decreasing sub clinical inflammation.

The investigators hypothesise that carnosine supplementation will reduce type 2 diabetes and cardiovascular risk factors by lowering chronic low-grade inflammation (CLI), oxidative stress, advanced glycation end products (AGEs), and advanced lipoxidation end products (ALEs).

Aim :To determine the capacity of carnosine supplementation to decrease major risk factors for type 2 diabetes and cardiovascular disease and identify metabolic pathways involved, specifically by:

1. Reducing diabetes risk (insulin sensitivity; secretory function and glucose tolerance)
2. Improving cardiovascular risk factors (lipids; arterial (aortic) stiffness; central blood pressure (cBP); endothelial function).
3. Decreasing the CLI, oxidative stress, AGEs, and ALEs, and increase detoxification of reactive carbonyl species (RCSs).

Conditions

  • Insulin Sensitivity

Interventions

DIETARY_SUPPLEMENT

carnosine

Carnosine capsules (2g) twice per day for 14 weeks

OTHER

Placebo

Placebo (methylcellulose) capsules for control group identical to intervention capsules and dose

Sponsors & Collaborators

Principal Investigators

  • Barbora de courten, MD,PHD,MPH · Monash University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-02-13
Primary Completion
2020-02-13
Completion
2020-06-12

Countries

  • Australia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02686996 on ClinicalTrials.gov